Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 07
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,319
-0.94%
|
$197,613
$27.0 P/Share
|
|
Jan 06
2025
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,311
-1.12%
|
$34,086
$26.61 P/Share
|
|
Jan 06
2025
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,195
-2.11%
|
$83,070
$26.61 P/Share
|
|
Jan 06
2025
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,873
-0.37%
|
$74,698
$26.61 P/Share
|
|
Jan 06
2025
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
3,133
-1.29%
|
$81,458
$26.61 P/Share
|
|
Jan 06
2025
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,982
-2.44%
|
$103,532
$26.61 P/Share
|
|
Jan 06
2025
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,375
-0.42%
|
$139,750
$26.61 P/Share
|
|
Jan 02
2025
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,948
+3.57%
|
-
|
|
Jan 02
2025
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,990
+6.45%
|
-
|
|
Jan 02
2025
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
46,525
+22.19%
|
-
|
|
Jan 02
2025
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
53,990
+18.22%
|
-
|
|
Jan 02
2025
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,990
+26.25%
|
-
|
|
Jan 02
2025
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
23,474
+16.72%
|
-
|
|
Dec 31
2024
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
298
+0.25%
|
$5,066
$17.57 P/Share
|
|
Dec 31
2024
|
Yvonne Hui Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
388
+1.41%
|
$6,596
$17.57 P/Share
|
|
Dec 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
24
-0.27%
|
$600
$25.38 P/Share
|
|
Dec 18
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
3,495
-2.92%
|
$83,880
$24.88 P/Share
|
|
Dec 17
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
61
-0.34%
|
$1,525
$25.41 P/Share
|
|
Dec 16
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
35
-0.39%
|
$840
$24.88 P/Share
|
|
Dec 16
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
861
-0.35%
|
$21,525
$25.26 P/Share
|
|
Dec 16
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
861
+0.35%
|
$3,444
$4.71 P/Share
|
|
Dec 13
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
20,565
-7.81%
|
$514,125
$25.04 P/Share
|
|
Dec 13
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,565
+7.24%
|
$82,260
$4.71 P/Share
|
|
Dec 11
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
18,574
-7.11%
|
$464,350
$25.1 P/Share
|
|
Dec 11
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,574
+6.63%
|
$74,296
$4.71 P/Share
|
|
Dec 11
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
11,853
-5.92%
|
$284,472
$24.85 P/Share
|
|
Dec 10
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,000
-3.32%
|
$600,000
$24.09 P/Share
|
|
Dec 03
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
25,447
-21.4%
|
$508,940
$20.93 P/Share
|
|
Dec 02
2024
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
15,152
-5.87%
|
$318,192
$21.01 P/Share
|
|
Dec 02
2024
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,152
+5.55%
|
$30,304
$2.03 P/Share
|
|
Oct 31
2024
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
546
+1.47%
|
$9,828
$18.29 P/Share
|
|
Oct 31
2024
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
546
+1.15%
|
$9,828
$18.29 P/Share
|
|
Oct 31
2024
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
546
+1.31%
|
$9,828
$18.29 P/Share
|
|
Oct 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,100
-0.55%
|
$22,000
$20.49 P/Share
|
|
Oct 16
2024
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
423
-1.55%
|
$8,883
$21.33 P/Share
|
|
Oct 15
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
864
-0.88%
|
$18,144
$21.03 P/Share
|
|
Oct 15
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
1,212
-1.0%
|
$25,452
$21.03 P/Share
|
|
Oct 15
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,843
-0.24%
|
$38,703
$21.03 P/Share
|
|
Oct 15
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
2,011
-0.99%
|
$42,231
$21.03 P/Share
|
|
Oct 15
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,089
-0.25%
|
$64,869
$21.03 P/Share
|
|
Oct 15
2024
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,791
-4.69%
|
$55,820
$20.97 P/Share
|
|
Oct 15
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
624
-0.52%
|
$13,104
$21.03 P/Share
|
|
Sep 19
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
24
-0.27%
|
$576
$24.04 P/Share
|
|
Sep 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
61
-0.67%
|
$1,464
$24.09 P/Share
|
|
Sep 17
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
36
-0.4%
|
$864
$24.77 P/Share
|
|
Sep 12
2024
|
Lisa Egbuonu Davis Director |
SELL
Open market or private sale
|
Direct |
1,400
-7.17%
|
$32,200
$23.03 P/Share
|
|
Sep 11
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,072
-1.68%
|
$47,656
$23.36 P/Share
|
|
Sep 10
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,295
-0.43%
|
$121,785
$23.25 P/Share
|
|
Sep 10
2024
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
744
-2.42%
|
$17,112
$23.25 P/Share
|
|
Sep 10
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,502
-3.43%
|
$80,546
$23.25 P/Share
|